PUBLISHER: The Business Research Company | PRODUCT CODE: 1938640
PUBLISHER: The Business Research Company | PRODUCT CODE: 1938640
Canine atopic dermatitis is a long-term, inflammatory skin disorder in dogs triggered by allergic reactions to environmental allergens like pollen, dust mites, mold, or certain foods. It is a hereditary condition that results in severe itching, skin redness, and frequent skin infections. The main goal of treating canine atopic dermatitis is to alleviate itching, decrease inflammation, and control secondary infections to enhance the dog's overall well-being.
The primary product categories used in the management of canine atopic dermatitis include glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies (mAbs), and other related therapies. Glucocorticoids are synthetic, broad-acting hormones that effectively relieve itching and inflammation by suppressing the immune response. This condition affects a variety of dog breeds, including German Shepherds, Terriers, Retrievers, and others, with common indications such as ectoparasites, food allergies, and allergic skin infections. Treatment methods include oral, topical, and injectable routes, and these products are distributed through veterinary clinics, retail pharmacies, online pharmacies, and other distribution channels.
Tariffs have impacted the canine atopic dermatitis market by increasing the cost of imported biologics, monoclonal antibodies, and specialty medications, which has affected veterinary clinics and pharmacies, particularly in North America and Europe. Segments like mAbs and immunosuppressants are most affected due to high import dependency. On the positive side, tariffs are driving local manufacturing initiatives, encouraging regional production of targeted therapies, and potentially improving supply chain resilience in the long term.
The canine atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides canine atopic dermatitis market statistics, including canine atopic dermatitis industry global market size, regional shares, competitors with a canine atopic dermatitis market share, detailed canine atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the canine atopic dermatitis industry. This canine atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The canine atopic dermatitis market size has grown rapidly in recent years. It will grow from $2.76 billion in 2025 to $3.05 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rising prevalence of allergic skin conditions in dogs, growing awareness among pet owners and veterinarians, limited availability of targeted therapies in the past, adoption of glucocorticoids and antihistamines as primary treatments, expansion of veterinary dermatology services.
The canine atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $4.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of novel biologics and mAbs, increasing investments in precision medicine for pets, rising adoption of topical and systemic immunotherapies, growth in online and retail distribution channels, focus on preventive and supportive care including nutraceuticals. Major trends in the forecast period include increasing use of monoclonal antibodies (mabs) for targeted therapy, growing adoption of allergen-specific immunotherapy (asit) in dogs, rising demand for medicated shampoos and topical treatments, expansion of nutraceuticals and probiotics for skin barrier support, focus on breed-specific treatment approaches for canine atopic dermatitis.
The growing number of skin allergy cases in dogs is expected to drive the expansion of the canine atopic dermatitis market. Skin allergies in dogs occur when their immune system overreacts to allergens like pollen, certain foods, or flea bites, leading to symptoms such as itching, redness, and irritation. This increase is partly due to greater exposure to environmental pollutants and allergens, which can trigger intensified immune responses and cause skin discomfort. Treatments for canine atopic dermatitis help alleviate these issues by minimizing inflammation and itching, as well as preventing secondary infections, thereby improving dogs' skin health and comfort. For example, in January 2024, the National Institutes of Health (NIH), a US-based government agency, reported that 7,915 dog owners (28.7%) indicated their dogs had experienced skin-related conditions. The data showed a steady increase in skin issues with age, from 7% in puppies to 37% in senior dogs. This rising prevalence is contributing to the growth of the canine atopic dermatitis market.
The increase in pet ownership is also contributing to the growth of the canine atopic dermatitis market. Pet ownership involves caring for domesticated animals, such as dogs, cats, and other companions, within a household setting. A key driver of this trend is the growing humanization of pets, where animals are increasingly seen as family members and sources of emotional support and companionship. Addressing canine atopic dermatitis plays an essential role in improving pets' lives by easing chronic itching and inflammation, enhancing skin health, and boosting overall comfort and well-being. For instance, in April 2025, the American Pet Products Association (APPA), a US-based trade association, reported that 94 million US households (71%) owned a pet, up from 86.9 million households (66%) in 2023-2024. As a result, the increase in pet ownership is fueling demand in the canine atopic dermatitis market.
Leading companies in the canine atopic dermatitis market are pursuing regulatory approvals to expand the global reach and availability of their treatments. Regulatory approvals are formal authorizations granted by health authorities after verifying that medical products meet safety, efficacy, and quality standards through comprehensive testing. For example, in September 2024, Elanco Animal Health Inc., a US-based pharmaceutical company focused on animal health, received US FDA approval for Zenrelia, a once-daily oral JAK inhibitor designed to treat allergic and atopic dermatitis in dogs. Zenrelia represents a significant innovation by addressing chronic, acute, or seasonal itching and inflammation with a single daily tablet. It functions by targeting the source of the itch and blocking the signaling pathways responsible for allergic reactions, thereby breaking the itch-scratch cycle. The treatment provides noticeable improvement from the first dose and helps minimize rebound itching, which is a common drawback in dogs treated with competing JAK inhibitors.
Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill's Pet Nutrition Inc., Royal Canin SAS, Ceva Sante Animale S.A., Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Nextmune AB, OKAVA Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Toray Industries Inc., LEO Pharma A/S, PetIQ Inc., Hester Biosciences Limited, Ourofino Saude Animal, Swedencare AB, Orion Corporation, Norbrook Laboratories Ltd., AB Science SA.
North America was the largest region in the canine atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the canine atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The canine atopic dermatitis market consists of sales of products including medicated shampoos, hypoallergenic diets, omega-3 fatty acid supplements, skin barrier repair creams, and topical antimicrobial or antifungal treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Canine Atopic Dermatitis Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses canine atopic dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for canine atopic dermatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The canine atopic dermatitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.